Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on AnaptysBio (NASDAQ:ANAB) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
